Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330821 · ClinicalTrials.gov registry record · Phase 1
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Therapy-Related Acute Myeloid Leukemia, sponsored by University of Southern California.
- Active
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 5
- Study locations
NCT03330821 is a Phase 1 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Therapy-Related Acute Myeloid Leukemia that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 53 participants, below the 61-participant average among 21 other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials with a reported enrollment target (13% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03330821, a Phase 1 study of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Therapy-Related Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given pevonedistat, cytarabine, and idarubicin may work better in treating patients with acute myeloid leukemia.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
- DRUG Idarubicin
- OTHER Pharmacological Study
- DRUG Pevonedistat
Study Locations (5)
California
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
Arizona
- University of Arizona Cancer Center - North Campus - Tucson
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330821
The ClinicalTrials.gov registry entry for NCT03330821 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 21 other Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials with a reported enrollment target (13% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03330821 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03330821 about?
NCT03330821 is a clinical study titled "Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia". This phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell ...
What is the current status of trial NCT03330821?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2018-04-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03330821 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
What interventions are being tested in trial NCT03330821?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Idarubicin (DRUG), Pharmacological Study (OTHER), Pevonedistat (DRUG).
Who is sponsoring clinical trial NCT03330821?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03330821 being conducted?
This trial has 5 study locations across Arizona, California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RECRUITING · Phase 1
-
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
All registered trials for this condition
Therapy-Related Acute Myeloid Leukemia
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.